Collectively, these results suggest that OR2B11 may serve as a potential therapeutic target for GBM by promoting mesenchymal transition and immunosuppressive TME through TAM regulation, potentially driving aggressive tumor behavior. Here, OR2B11 is linked to neoplasm.